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Background: Optic neuritis is a frequent manifestation of multiple sclerosis. Visual deficits range from a minor
impairment of visual functions through to complete loss of vision. Although many patients recover almost
completely, roughly 35% of patients remain visually impaired for years, and therapeutic options for those patients
hardly exist. Vision restoration therapy is a software-based visual training program that has been shown to improve
visual deficits after pre- and postchiasmatic injury. The aim of this pilot study is to evaluate whether residual visual
deficits after past or recent optic neuritis can be reduced by means of vision restoration therapy.
Methods/design: A randomized, controlled, patient- and observer-blinded clinical pilot study (VISION study) was
designed to evaluate the efficacy of vision restoration therapy in optic neuritis patients. Eighty patients with a
residual visual deficit after optic neuritis (visual acuity ≤0.7 and/or scotoma) will be stratified according to the time
of optic neuritis onset (manifestation more than 12 months ago (40 patients, fixed deficit) versus manifestation 2 to
6 months ago (40 patients, recent optic neuritis)), and randomized into vision restoration therapy arm or saccadic
training arm (control intervention). Patients will be instructed to complete a computer-based visual training for
approximately 30 minutes each day for a period of 6 months. Patients and evaluators remain blinded to the
treatment allocation throughout the study. All endpoints will be analyzed and P-values< 0.05 will be considered
statistically significant. The primary outcome parameter will be the expansion of the visual field after 3 and
6 months of treatment as determined by static visual field perimetry and high resolution perimetry. Secondary
outcome variables will include visual acuity at both low and high contrast, glare contrast sensitivity, visually evoked
potentials, optical coherence tomography and other functional tests of the visual system, alertness, health-related
quality of life, fatigue, and depression.
Discussion: If vision restoration therapy is shown to improve visual function after optic neuritis, this method might
be a first therapeutic option for patients with incomplete recovery from optic neuritis.
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Multiple sclerosis (MS) is one of the most frequent
chronic diseases of the central nervous system (CNS) in
young adults in western countries. The underlying
pathomechanism is considered to be an autoimmune
mediated attack against CNS structures that leads to
CNS demyelination and neuroaxonal degeneration, and
ultimately results in CNS dysfunction [1]. The course of
the disease is typically relapsing-remitting in the begin-
ning, followed by a secondary chronically progressive
phase that is characterized by the accumulation of per-
sistent neurological deficits. The therapeutic options
comprise high-dose glucocorticosteroids in the acute
phase and long-term immunomodulation or -
suppression depending on the course and the dynamics
[2]. An optic neuritis (ON) is the first symptom in 20 to
30% of MS patients, and approximately 50% of MS
patients develop an ON at some point [3-6]. Leading
symptoms of ON are reduced visual acuity, periocular
pain (especially during eye movements), reduced con-
trast sensitivity, dysfunction of color vision, and visual
field defects. In the majority of cases the loss of vision
develops subacutely over a few days, whereas the recov-
ery of the visual functions usually takes some weeks [3].
Although many patients recover almost completely,
roughly 35% of patients remain visually impaired even
after 10 years of onset [7,8]. Importantly, incomplete re-
covery of vision often leads to a reduced quality of life
[9], and therapeutic options for those patients hardly
exist [10].
Previous studies suggest beneficial effects of neuro-
plastic approaches for the treatment of visual deficits of
neurological etiology [8,9]. Based on experiments with
repetitive measurements of incremental thresholds at
the edges of absolute visual field defects, Kasten and col-
leagues developed a software-based training program
which is referred to as “vision restoration therapy”
(VRT) [11]. The program (NovaVision AG, Magdeburg,
Germany) can be run on a standard personal computer,
which makes it suitable for home-based training. In a
randomized, placebo-controlled, double-blind study on
patients with pre- and postchiasmatic injury, VRT treat-
ment expanded the mean visual field in the postchias-
matic group by 4.9° (± 1.7) whereas the mean visual field
of the placebo group was reduced by 0.9° (± 0.8). The
subgroup of patients with optic nerve injuries showed a
trend towards a visual field expansion of 5.8° (± 1.2) in
the VRT group compared to 4.3° (± 0.7) in the placebo
group [11]. In patients with anterior ischemic optic
neuropathy (AION), VRT resulted in a significant im-
provement of binocular reading speed and revealed posi-
tive trends on improvement of visual acuity, foveal
sensitivity, and high-resolution perimetry (HRP). More-
over, all patients reported a subjective improvement oftheir visual function [12]. VRT is based on the hypoth-
esis that visual units which are excluded from visual pro-
cessing can be reintegrated by specific visual
stimulation. Because of the diffuse nature of optic nerve
lesions it is assumed that a smooth transition exists be-
tween severely and only moderately damaged retinal
ganglion cells. Anope areas might, therefore, contain a
number of capable but inhibited neurons. In fact, it has
been demonstrated that even cortical blind patients have
a residual visual sensitivity [13], and peripheral visual
stimulation induced neural activity of central retinal gan-
glion cells in eyes with age-related macular degeneration
[14]. It therefore appears likely that VRT stimulates re-
sidual retinal ganglion cells in visually impaired post-ON
patients, and thus improves visual function [15-21].
Against this background, we introduce the protocol
for a randomized, controlled clinical pilot study evaluat-
ing the efficacy of VRT in patients with incomplete vis-
ual recovery upon ON. We hypothesize that VRT is
superior to saccadic training which is used here as a
control intervention, with respect to i) restitution of re-
sidual visual field defects; ii) additional parameters of
both visual function and integrity of the visual system
including low contrast and color vision, conductivity,
and retinal morphology; and iii) improvement in quality
of life estimates.
Methods/design
Design and setting
The VISION study is a monocentric, randomized, con-
trolled, and double-blind clinical trial conducted at the
NeuroCure Clinical Research Center at the Charité -
Universitaetsmedizin, Berlin, Germany. Recruitment
started in 2011. Eighty patients with a diagnosis of past
or recent ON will be stratified according to the onset of
ON. The first group will comprise patients with ON
manifestation at least 1 year in the past. The second
group will comprise patients with ON onset between 2
and 6 months in the past. These two groups will be ran-
domized 1:1 into the VRT group and the control inter-
vention group, with the latter receiving a saccade
training (RehaCom, Hasomed GmbH, Magdeburg, Ger-
many). The detailed study design is provided below
according to the revised CONSORT statement [22,23].
Study cohort
Inclusion criteria for participation are: age between 18
and 55 years, ability to provide written informed con-
sent, definite history of ON (supported by objective
criteria-like visual evoked potentials (VEP) and/or typ-
ical clinical presentation), visual acuity between 0.05
(20/400) and 0.7 (~20/29) or >0.7 and scotoma (a basic
visual function must be present to perform the training),
and no systemic steroid treatment or plasmapheresis
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currence of ON ≤ 60 days to avoid confounding by spon-
taneous resolving optic nerve edema, any other
potentially confounding eye diseases (for example,
macular degeneration, cataract, glaucoma, diabetic retin-
opathy), nystagmus, strabismus and amblyopia to avoid
fixation errors and impaired binocular function, and a
history of epileptic seizures because of repeated presen-
tation of bright light stimuli.
Randomization and blinding
A freeware program (www.random.org) is used to
randomize subjects into VRT and control groups.
Randomization is performed by an independent person
otherwise not involved in the study. Access to the
randomization lists is restricted to this person ensuring
that the treatment allocation remains concealed to the
recruiting and enrolling study personnel. Two members
of the study team remain unblinded (KB, SW) in order
to instruct and guide patients in all treatment-specific
software issues. All information that could possibly re-
veal the study arm to both patients and blinded evalua-
tors, such as the brand names or labels of the software
or user manuals, are carefully avoided. All outcome
parameters are determined in a blinded fashion. Patients
asking for disclosure of treatment allocation will be put
off until the end of the study.
Ethics
The VISION study has been approved by the local ethics
committee (Charité Campus Mitte; Berlin/Germany; no.
EA1/078/10) and the Data Protection Department of the
Charité and is registered at Clinicaltrials.gov
(NCT01274702). The study will be conducted in accord-
ance with the Declaration of Helsinki in its current ver-
sion, the guidelines of the International Conference on
Harmonization of Good Clinical Practice (ICH-GCP),
and the applicable German laws. All participants are
required to give informed written consent. No patient
will be deprived of receiving a standard therapy.
Treatment
Vision restoration therapy
VRT is a commercially distributed computer-based vis-
ual training program (NovaVison AG, Magdeburg, Ger-
many). This software is based on the measurement of
the visual field at baseline using HRP that detects the
horizontal 43 degrees and vertical 32 degrees of the vis-
ual field like a common perimeter with supra-threshold
stimuli and a higher resolution. The aim is to determine
the border between a scotoma and normal areas of the
visual field in a more precise way than standard auto-
mated perimetry does. The VRT software uses algo-
rithms based on the HRP data to stimulate specificallyreceptive fields close to scotoma borders. VRT is per-
formed using a chin support placed in front of the moni-
tor at a distance according to the size of the monitor to
ensure that the light beam of the stimuli reaches the cor-
rect areas of the retina. Patients are instructed to exer-
cise for 30 minutes every day over a total period of
6 months. During each training session, 400 white light
supra-threshold stimuli are presented on a computer-
screen (duration 2000 ms each) and have to be con-
firmed by the patients by pressing a key within 1000 ms.
Central fixation is important and is facilitated by a cen-
tral color-changing dot (31 pixels) on which the patient
continuously has to fixate and confirm each color
change by pressing a key. For a maximum training ef-
fect, stimulus parameters such as the areas of stimulus
presentation, stimulus size, duration and brightness
undergo monthly adaptation to any change in the visual
field.
Control intervention
The control treatment is a computer-based training for
rapid eye movements and is part of a comprehensive
cognitive rehabilitation/brain performance training soft-
ware suite (RehaCom, Hasomed GmbH, Magdeburg,
Germany) [24]. The patient is asked fixate a central tar-
get and to respond to peripheral stimuli moving towards
the center of the visual field. As in the VRT arm, a chin
support is provided. Some guidance is given, for example
a horizontal line that facilitates the differentiation be-
tween the fixation target and the moving object. The
program has ascending levels of difficulty depending on
the size, the contrast, and the velocity of the moving ob-
ject. As in the VRT arm, patients are instructed to exer-
cise for 30 minutes each day, for 6 months in total. The
control treatment enables the patient to compensate loss
of visual function by the use of saccadic eye movements
[25] rather than inducing a true recovery of visual
dysfunction.
Outcome parameters
The primary outcome parameter is the extend of the vis-
ual field after 3 and 6 months of training as determined by
both HRP (see above) and threshold 30 degree automated
perimetry (HFA 720, Zeiss Meditec AG, Germany). The
secondary outcome parameters are outlined below and
will be evaluated as displayed in Table 1. Visual acuity
measurements are made using the Freiburg Visual Acuity
and Contrast Test (FRACT): Landolt rings (ISO 8596)
with a constant high contrast and decreasing size are pre-
sented at 4 m distance on a computer screen, and the pa-
tient is asked to report the perceived direction of the
opening of each Landolt ring presented [26]. Contrast
sensitivity is measured using FRACT with Landolt rings
of equal size but decreasing contrast. Measurements of
Table 1 Visits and measurements
Measurements Visit 0
(baseline visit)
Visit 1
(after 3 months)
Visit 2
(after 6 months)
Neurostatus X
Visual field X X X
Contrast sensitivity X X X
Glare sensitivity X X X
Visual acuity X X X
Visual evoked
potentials
X X X
Optical coherence
tomography
X X X
Color perception X X X
Binocular vision X X X
Eye movement/ X X X
Leading eye reading
speed
X X X
Trial making test X X X
Alertness X X X
Health related
quality of life
X X X
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gram as described above and a purpose built glare source
(Beuth University of Applied Sciences, Berlin, Germany).
The glare source consists of a white frame with eight
white LEDs (approximately 8,500 LUX each) circularly
arranged around the TFT-screen used for FRACT testing.
Recording of VEP allows the conductance velocity and the
amplitude of the visual signal evoked by stimulating the
retina to be measured. In ON, both a delay of latency and
lowered amplitude of this signal is typical. Spectral do-
main optical coherence tomography (OCT; Spectralis,
Heidelberg Engineering, Germany; software version 5.1) is
used to measure the retinal nerve fiber layer thickness
(RNFLT) of the retina circularly around the optic nerve
head and the volume of the macula, as both parameters
are increasingly recognized as markers for neuroaxonal
degeneration in MS [27]. Color perception is tested using
pseudo-iso-chromatic plates (Ishihara, 14-plate version)
and a Multi Color Anomaloscope (HMC, Oculus GmbH,
Wetzlar, Germany), whereby the Ishihara test serves as a
screening-test which is followed by an anomaloscope
measurement in case of any abnormality [28]. The quality
of stereoscopic vision is assessed using the stereo fly test
(Titmus test). The patient wears polarized glasses and
views a polarized fly. In normal stereoscopic vision a
three-dimensional image of the fly is perceived. The
cover/uncover test is performed to detect any strabismus
or heterophoria. The International Reading Speed
Texts (IReST) are used to measure the reading abil-
ity [29]. The Trail Making Test (TMT) is a popularneuropsychological test that provides information on
visual search, scanning, speed of processing, mental
flexibility, and executive functions. The patient is
asked to connect 25 randomly spread numbers on a
sheet of paper, and the time required for this task is
measured [30]. The Tests of Attentional Performance
(TAP 1.7) measure alertness via reaction time and provide
a global measure of processing speed of the brain [31].
Alertness is defined as a state of general wakefulness in
which a person can quickly react to concrete require-
ments. The questionnaires that are used to evaluate the
health-related quality of life (HRQL) with regard to vision
are the National Eye Institute Visual Functioning Ques-
tionnaire (NEI-VFQ 39) [32], the Impact of Visual Impair-
ment Scale (IVIS) (which is the visual subscale of the
Multiple Sclerosis Questionnaire of Life Inventory
(MSQLI)) and a Visual Analogue Scale (VAS). The Short
Form 36 (SF-36) is a generic measurement of the HRQL
[33,34], the Health 49 is a freely available questionnaire
(www.hamburger-module.de) [35] and the Fatigue Severity
Scale (FSS) is a self-rating, nine-item questionnaire which
measures the severity of fatigue [36] which has been vali-
dated in a large sample of MS patients [37]. The Beck De-
pression Inventory (BDI) is used mainly to control for
depression as a possible confounder [38]. Finally, the fol-
lowing demographic data will be collected: disease course
(clinically isolated syndrome or relapsing-remitting MS or
secondary-progressive MS [39], date of first manifestation,
date of first diagnosis, side of ON, current treatment,
expanded disability status scale [40]), and vital parameters
(blood pressure, heart rate, weight, body height, age, and
ethnicity).
Statistical analysis
This study is designed as a pilot study because sufficient
data that would allow a reasonable a priori calculation
of sample size are not yet available. All endpoints will be
analyzed and described descriptively. The null hypoth-
esis is as follows: VRT has no influence on the visual
outcome after ON. Evaluation of endpoints will be car-
ried out by both “intention-to-treat” and “per-protocol”
analyses. Statistical tests and presentations will be appro-
priate to the category and distribution of the respective
variables. All tests will be accomplished with a type one
error (α= 0.05; bilateral). All calculations will be per-
formed using SPSS, Version 20 (SPSS, Inc., Chicago, IL,
USA).
Discussion
ON is among the most common manifestations of MS
and, although the prognosis is usually quite good, a sub-
stantial number of patients retain some degree of visual
dysfunction which often has a negative impact on their
quality of life [3]. Currently, there are no established
therapeutic options for a residual visual deficit after ON.
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patients suffering from visual impairment after ON.
Some mechanisms have been discussed to explain the
functionality of the VRT stimulations: neuroplasticity
leading to an optimization of the synaptic connectivity
and cortical changes of the structure, activation of par-
tially damaged visual units, an increase in the velocity of
the visual information processing, and an increase in the
general visual attention [11,12,41]. However, since the
efficacy of VRT for other neurological disorders has been
repeatedly questioned [42] some important issues need
to be addressed. For example, sufficient control of cen-
tral fixation is crucial to rule out any eye movements
during training sessions. Furthermore, the training effect
needs to be robust enough to be of clinical relevance
and should be detectable not only by HRP. Finally, a pla-
cebo effect needs to be sufficiently ruled out. Most of
these points have been addressed in a study that con-
firmed the efficacy of VRT in 302 patients with visual
deficits due to cerebral ischemia, hemorrhage, head
trauma, tumor removal, and anterior ischemic optic
neuropathy [41]. The treatment response was independ-
ent of eye movement and could be confirmed by con-
ventional perimetry. Although the study protocol of the
VISION study addresses these issues, some important
limitations need to be considered. First, given the rather
small sample size of 40 patients in each group with past
and recent ON (20 patients per treatment arm) the
study might be underpowered to detect small treatment
effects. On the other hand, in the previous study by Kas-
ten and collegues [11], a treatment effect could be
detected in an even smaller cohort. Moreover, since this
is the first study that addresses a potential therapeutic
effect of VRT in patients with incompletely recovered
ON, the intention is rather to corroborate the hypoth-
esis, which then clearly needs to be confirmed in a larger
study with a statistically sound sample-size calculation.
Second, one might argue that the saccadic training per-
formed by the patients in the control arm is not an ap-
propriate control intervention since one might suspect
both an intrinsic therapeutic effect on some visual para-
meters and an unintentional unblinding. However, creat-
ing a real training placebo is methodologically difficult
because it is likely that any stimulation may result in an
activation of the neuronal network [12]. We chose the
saccadic training because mechanisms other than neuro-
plasticity are considered as being crucial for a potential
treatment effect. In saccadic training the patient learns
to compensate the lost function by the use of saccadic
movements of the eye. It is believed that patients disre-
gard anope areas so that an increase of the amplitude of
saccadic movements would help them to extend the
affected search field [43]. Thus, saccadic training would
not result in a real resolution of a visual field defect.Furthermore, despite major efforts, the maintenance of
patient blinding remains challenging since the proce-
dures of VRT and control intervention are not exactly
identical. Finally, vision in general is a complex process
that is dependent on many factors (for example, day-
light, fatigue, attention, etc.) that cannot be taken into
consideration due to practicability and other unknown
factors.
In conclusion, VRT has the potential to be the first ef-
fective restorative treatment option for patients suffering
from persistent visual deficits after ON. The intention of
the VISION study is to corroborate this hypothesis be-
fore the initiation of larger, confirmatory trials.
Trial status
The VISION study is currently recruiting patients. Six-
teen patients have already been randomized, six of them
have completed the 6 months of treatment.
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